CRNX
Crinetics Pharmaceuticals, Inc.
Next earnings Aug 5, 2026 (after close) · consensus $-1.26 EPS, $15.1M rev
Last earnings +4.3% on 2026-05-07
$36.70
▲ +4.89%$36.70▲ +22.70%
over 1Y
L $26.85EODHDH $56.43
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.9%
1W+3.7%
1M-0.2%
3M+9.0%
YTD-21.5%
1Y+22.7%
Hold
Conviction
Horizon
Long (>12mo)
Street · 22 analysts
Buy
Newly commercial endocrine biotech with PALSONIFY launch + $1.4B cash post-raise, but valuation is a story stock at 492x sales.
Revenue $7.70M · FY2025
Crinetics just crossed the most important threshold in biotech: PALSONIFY (paltusotine) received FDA approval on September 25, 2025 as the first and only once-daily oral somatostatin receptor ligand for acromegaly, and the MD&A reports $5.4M of net product revenue in Q4 2025 alone — meaning the bulk of FY2025's $7.7M revenue came from just one commercial quarter, with launch metrics (200+ enrollment forms, 125+ unique prescribers, ~50% reimbursed without bridge supplies) that look orderly for a rare-disease launch. The CHMP positive opinion in February 2026 puts EU approval on track for H1 2026, and the pipeline behind PALSONIFY (atumelnant in CAH with Phase 3 CALM-CAH and Phase 2/3 BALANCE-CAH dosing started, CRN09682 in Phase 1/2) is genuinely deep for a sub-$4B company.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.01M | $1.04M | $7.70M |
| Gross profit | — | — | — | — | — |
| Operating income | -$108M | -$168M | -$223M | -$339M | -$517M |
| Net income | -$108M | -$164M | -$215M | -$298M | -$465M |
| Diluted EPS | -$2.80 | -$3.15 | -$3.69 | -$3.69 | -$4.95 |
| Net margin | — | — | -5345.9% | -28720.7% | -6046.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$3.74B
EV / EBITDA—
EV / Sales486.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-12.1%
FCF yield-10.0%
Quality & risk
ROIC (est.)-41.2%
Free cash flow-$384M
Total debt—
Net cash$102M
Altman Z-Score14.94 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+12.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-06-22
Annual meeting vote results filed; routine governance disclosure, no strategic change.
- 8-K Earnings results2026-05-07
Q1'26 10-Q post $380M raise; ~$1.4B liquidity funds CAH/acromegaly buildout.
- 10-Q Quarterly report2026-05-07
Q1'26 10-Q post $380M raise; ~$1.4B liquidity funds CAH/acromegaly buildout.
- DEF 14A Proxy statement2026-04-29
2026 proxy: director slate and exec comp post-commercial transition; routine.
- 8-K Officer / director change2026-04-10
Executive/director change disclosed; leadership transition during commercial ramp.
- 8-K Officer / director change2026-03-23
Officer/director change announced; potential leadership reshuffle post-launch.
- 8-K Auditor change2026-03-03
Change in independent auditor reported; routine but worth monitoring transition.
- 8-K Earnings results2026-02-26
FY25 10-K: PALSONIFY FDA-approved Sept'25, EU CHMP positive, atumelnant Ph3 dosed.
- 10-K Annual report2026-02-26
FY25 10-K: PALSONIFY FDA-approved Sept'25, EU CHMP positive, atumelnant Ph3 dosed.
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-182026-06-22open ↗4Period ending 2026-06-172026-06-18open ↗144Filing2026-06-17open ↗4Period ending 2026-05-292026-06-02open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Crinetics Pharmaceuticals, Inc. (CRNX) a buy?
- CRNX currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Newly commercial endocrine biotech with PALSONIFY launch + $1.4B cash post-raise, but valuation is a story stock at 492x sales.
- What is Crinetics Pharmaceuticals, Inc.'s quality score?
- CRNX scores 40.058823529411754/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001658247, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 1:16:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.